SML4082
Paliperidone Palmitate
≥98% (HPLC)
别名:
3-(2-(4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yl palmitate, 9-Hydroxyrisperidone palmitate, Hexadecanoic acid 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl ester, RO 92670
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to beige
溶解性
soluble (DMSO:TFA, 2 mg/mL, clear (add 1 drop TFA))
储存温度
-10 to -25°C
SMILES字符串
Fc1cc2[o]nc(c2cc1)C3CCN(CC3)CCC4=C(NC5=C(CCCN5C4=O)OC(=O)CCCCCCCCCCCCCCC)C
InChI key
YOSKWMGLLZWACB-UHFFFAOYSA-N
生化/生理作用
Prodrug form of paliperidone, is a long-acting injectable antipsychotic that targets dopamine and serotonin receptors.
Paliperidone palmitate is a long-acting injectable form of paliperidone, an atypical antipsychotic that targets dopamine D2 and serotonin 5-HT2A receptors to alleviate schizophrenia symptoms through neurotransmission regulation. Paliperidone palmitate also interacts with α1/α2 adrenergic and H1 histaminergic receptors, influencing both its therapeutic effects and side effect profile. The formulation′s sustained release mechanism promotes gradual absorption, ensuring stable drug levels for prolonged efficacy.
Paliperidone palmitate is a long-acting injectable form of paliperidone, an atypical antipsychotic that targets dopamine D2 and serotonin 5-HT2A receptors to alleviate schizophrenia symptoms through neurotransmission regulation. Paliperidone palmitate also interacts with α1/α2 adrenergic and H1 histaminergic receptors, influencing both its therapeutic effects and side effect profile. The formulation′s sustained release mechanism promotes gradual absorption, ensuring stable drug levels for prolonged efficacy.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
Translational Psychiatry, 12(1), 519-519 (2022)
Dean Najarian et al.
The international journal of neuropsychopharmacology, 25(3), 238-251 (2021-11-19)
This double-blind (DB), randomized, parallel-group study was designed to evaluate efficacy and safety of paliperidone palmitate 6-month (PP6M) formulation relative to paliperidone palmitate 3-month (PP3M) formulation in patients with schizophrenia. Following screening, patients entered an open-label (OL) maintenance phase and
L E van Beijsterveldt et al.
Psychopharmacology, 114(1), 53-62 (1994-02-01)
Risperidone is a new benzisoxazole antipsychotic. 9-Hydroxy-risperidone is the major plasma metabolite of risperidone. The pharmacological properties of 9-hydroxy-risperidone were studied and appeared to be comparable to those of risperidone itself, both in respect of the profile of interactions with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持